<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mann, Kate</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Stenlöf, Kaj</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Long-term Canagliflozin is Efficacious and Generally Well Tolerated in Older Patients</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-11-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">9-10</style></pages><abstract><style  face="normal" font="default" size="100%">Treatment of the older patients with T2DM can be complex given that these patients often have advanced T2DM, multiple comorbidities, and need combination therapy. This article presents the results of a double-blind phase 3 study of the sodium-glucose cotransporter 2 inhibitor canagliflozin in patients aged 55 to 80 years.</style></abstract><number><style face="normal" font="default" size="100%">32</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>